Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Effects of fluvastatin on insulin resistance and cardiac morphology in hypertensive patients

Journal of Human Hypertension volume 25, pages 492–499 (2011)Cite this article

Subjects

Abstract

Among hypertensive patients, cardiovascular disease morbidity is common, even in those who are adequately treated. New pharmacological strategies to mitigate the burden of arterial hypertension are needed. This 12-month, randomized, double-blind placebo-controlled study investigated the effect of statin (fluvastatin) treatment on ambulatory blood pressure (ABP), exercise blood pressure (EBP), myocardial structure, endothelial function and insulin resistance in 50 hypertensive patients. At baseline, the groups were comparable in terms of demographic characteristics, ABP, EBP, endothelial function and homeostasis model assessment of insulin resistance (HOMA-IR). At the end of the study, there was no difference between groups in terms of resting systolic blood pressure. However, maximum systolic EBP was lower in the treatment group than in the placebo group (175±18 vs 192±23 mm Hg, P<0.05), as was left ventricular mass index (LVMI; 82±15 vs 100±23, P<0.05), and HOMA-IR index was lower after fluvastatin treatment (2.77±1.46 vs 3.33±1.73, P<0.05). Changes in lipid profile were not correlated with blood pressure, endothelial function, LVMI or HOMA-IR data. In hypertensive patients, fluvastatin can improve maximum systolic EBP, myocardial remodelling and insulin resistance, independently of lipid profile variations and endothelial function.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  1. Kannel WB . Blood pressure as a cardiovascular risk factor: prevention and treatment. JAMA 1996; 275: 1571–1576.

    Article  CAS  PubMed  Google Scholar 

  2. Neaton JD, Blackburn H, Jacobs D, Kuller L, Lee DJ, Sherwin R et al. Serum cholesterol level and mortality findings for men screened in the Multiple Risk Factor Intervention Trial: Multiple Risk Factor Intervention Trial Research Group. Arch Intern Med 1992; 152: 1490–1500.

    Article  CAS  PubMed  Google Scholar 

  3. Wilhelmsen L, Pyorala K, Wedel H, Cook T, Pedersen T, Kjekshus J . Risk factors for a major coronary event after myocardial infarction in the Scandinavian Simvastatin Survival Study (4S): impact of predicted risk on the benefit of cholesterol-lowering treatment. Eur Heart J 2001; 22: 1119–1127.

    Article  CAS  PubMed  Google Scholar 

  4. Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383–1389.

    Google Scholar 

  5. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG et al. The effects of pravastatin on coronay events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial Investigators. N Engl J Med 1996; 335: 1001–1009.

    Article  CAS  PubMed  Google Scholar 

  6. Schawrtz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D et al. Myocardial Ischemia Reduction with Aggressive Cholesterol lowering (MIRACL) Study Investigators. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 2001; 285: 1711–1718.

    Article  Google Scholar 

  7. The Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339: 1349–1357.

    Article  Google Scholar 

  8. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TextCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998; 279: 1615–1622.

    Article  CAS  PubMed  Google Scholar 

  9. Sheperd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995; 333: 1301–1307.

    Article  Google Scholar 

  10. Calermajer DS, Sorensen KE, Gooch VM, Spiegelhalter DJ, Miller OI, Sullivan ID et al. Non-invasive detection of endothelial dysfunction in children and adult at risk of atherosclerosis. Lancet 1992; 340: 1111–1115.

    Article  Google Scholar 

  11. Taylor A, Zhu D, Sullenberger LE, Lee HJ, Lee JK, Grace KA . Relationship between glycemic status and progression of carotid intima-media thickness during treatment with combined statin and extended-release niacin in ARBITER 2. Vasc Health Risk Manag 2007; 3: 159–164.

    CAS  PubMed  PubMed Central  Google Scholar 

  12. Bauersachs J, Galuppo P, Fraccarollo D, Christ M, Ertl G . Improvement of left ventricular remodeling and function by hydroxymethylglutaryl coenzyme A reductase inhibition with cerivastatin in rats with heart failure after myocardial infarction. Circulation 2001; 104: 982–985.

    Article  CAS  PubMed  Google Scholar 

  13. Yu Y, Ohmori K, Chen Y, Sato C, Kiyomoto H, Shinomiya K et al. Effects of pravastatin on progression of glucose intolerance and cardiovascular remodeling in a type II diabetes model. J Am Coll Cardiol 2004; 44: 904–913.

    Article  CAS  PubMed  Google Scholar 

  14. Dechend R, Fielbeler A, Park JK, Muller DN, Theuer J, Mervaala E et al. Amelioration of angiotensin II-induced cardiac injury by a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Circulation 2001; 104: 576–581.

    Article  CAS  PubMed  Google Scholar 

  15. Xu Z, Okamoto H, Akino M, Onozuka H, Matsui Y, Tsutsui H . Pravastatin attenuates left ventricular remodeling and diastolic dysfunction in angiotensin II induced hypertensive mice. J Cardiovasc Pharmacol 2008; 51: 62–70.

    Article  CAS  PubMed  Google Scholar 

  16. Loch D, Levick S, Hoey A, Bronw L . Rosuvastatin attenuates hypertension-induced cardiovascular remodeling without affecting blood pressure in DOCA-salt hypertensive rats. J Cardiovasc Pharmacol 2006; 47: 396–404.

    CAS  PubMed  Google Scholar 

  17. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7) 2003. JAMA 2003; 289: 2560–2572.

    Article  CAS  PubMed  Google Scholar 

  18. American Diabetes Association. Standards of medical care in diabetes 2006. Diabetes Care 2006; 29: S4–S85.

    Google Scholar 

  19. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC . Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412–419.

    Article  CAS  PubMed  Google Scholar 

  20. Corretti MC, Anderson TJ, Benjamin EJ, Celermajer D, Charbonneau F, Creager MA et al. Guidelines for ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery. J Am Coll Cardiol 2002; 39: 257–265.

    Article  PubMed  Google Scholar 

  21. Abetel G, Poget PN, Bonnabry JP . Hypontensive effect of an inhibitor of cholesterol synthesis (fluvastatin): a pilot study. Schweiz Med Wochenschr 1998; 128: 272–277.

    CAS  PubMed  Google Scholar 

  22. Raison J, Rudnichi A, Safar ME . Effects of atorvastatin on aortic pulse wave velocity in patients with hypertension and hypercholesterolaemia: a preliminary study. J Hum Hypertens 2002; 16: 705–710.

    Article  CAS  PubMed  Google Scholar 

  23. Tonolo G, Ciccarese M, Brizzi P, Puddu L, Secchi G, Calvia P et al. Reduction of albumin excretion rate in normotensive microalbuminuric type 2 diabetic patients during long-term simvastatin treatment. Diabetes Care 1997; 20: 1891–1895.

    Article  CAS  PubMed  Google Scholar 

  24. O’Callaghan CJ, Krum H, Conway EL, Lam W, Skiba MA, Howes LG et al. Short term effects of pravastatin on blood pressure in hypercholesterolemic hypertensive patients. Blood Press 1994; 3: 404–406.

    Article  PubMed  Google Scholar 

  25. Sposito AC, Mansur AP, Coelho OR, Nicolau JC, Ramirez JAF . Additional reduction in blood pressure after cholesterol-lowering treatment by statins (lovastatin or pravastatin) in hypercholesterolemic patients using angiotensin-converting enzyme inhibitors (enalapril or lisinopril). Am J Cardiol 1999; 83: 1497–1499.

    Article  CAS  PubMed  Google Scholar 

  26. Glorioso N, Troffa C, Filigheddu F, Dettori F, Soro A, Parpaglia PP et al. Effect of the HMG-CoA reductase inhibitors on blood pressure in patients with essential hypertension and primary hypercholesterolemia. Hypertension 1999; 34: 1281–1286.

    Article  CAS  PubMed  Google Scholar 

  27. Terzoli L, Mircoli L, Ferrari AU . Effect of statins on blood pressure (BP) assessed by ambulatory monitoring. J Hypertens 2001; 19: S188.

    Google Scholar 

  28. Strazzullo P, Kerry SM, Barbato A, Versiero M, D’Elia L, Cappuccio FP . Do statins reduce blood pressure? A meta-analysis of randomized, controlled trials. Hypertension 2007; 49: 792–798.

    Article  CAS  PubMed  Google Scholar 

  29. Wassmann S, Laufs U, Baumer AT, Muller K, Ahlbory K, Linz W et al. HMG-CoA reductase inhibitors improve endothelial dysfunction in normocholesterolemic hypertension via reduced production of reactive oxygen species. Hypertension 2001; 37: 1450–1457.

    Article  CAS  PubMed  Google Scholar 

  30. Ott C, Schlaich MP, Schmidt BMW, Titze SI, Schaufele T, Schmieder RE . Rosuvastatin improves basal nitric oxide activity of the renal vasculature in patients with hypercholesterolemia. Atherosclerosis 2008; 196: 704–711.

    Article  CAS  PubMed  Google Scholar 

  31. Song YS, Manson JE, Tinker L, Howard BV, Kuller LH, Nathan L et al. Insulin sensitivity and insulin secretion determined by homeostasis model assessment and risk of diabetes in a multiethinc cohort of women. Diabetes Care 2007; 30: 1747–1752.

    Article  PubMed  Google Scholar 

  32. Sari R, Eray E . The effect of atorvastatin treatment on insulin resistance, leptin, and highly sensitive C-reactive protein in hypercholesterolemic patients. Endocrinologist 2007; 17: 315–317.

    Article  Google Scholar 

  33. Sonmez A, Baykal Y, Kilic M, Yilmaz M, Saglam K, Bulucu F et al. Fluvastatin improves insulin resistance in nondiabetic dyslipidemic patients. Endocrine 2003; 22: 151–154.

    Article  CAS  PubMed  Google Scholar 

  34. Guclu F, Ozmen B, Hekimsoy Z, Kirmaz C . Effects of a statin group drug, pravastatin, on the insulin resistance in patients with metabolic syndrome. Biomed Pharmacol 2004; 58: 614–618.

    Article  Google Scholar 

  35. Freeman DJ, Norrie J, Sattar N, Neely RDG, Cobbe SM, Ford I et al. Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation 2001; 103: 357–362.

    Article  CAS  PubMed  Google Scholar 

  36. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7–22.

    Article  Google Scholar 

  37. Koh KK, Quon MJ, Han SH, Lee Y, Kim SJ, Shin EK . Atorvastatin causes insulin resistance and increases ambient glycemia in hypercholesterolemic patients. J Am Coll Cardiol 2010; 55: 1209–1216.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Cirrincione GM, Boluyt MO, Hwang HS, Bleske BE . 3-HMG-Coenzyme A reductase inhibitor and extracellular matrix gene expression in the pressure-overloaded rat heart. J Cardiovasc Pharmacol 2006; 47: 521–530.

    Article  CAS  PubMed  Google Scholar 

  39. De Lorgeril M, Salen P, Bontemps L, Belichard P, Geyssant A, Itti R . Effects of lipid-lowering drugs on left ventricular function and exercise tolerance in dyslipidemic coronary patients. J Cardiovasc Pharmacol 1999; 33: 473–478.

    Article  CAS  PubMed  Google Scholar 

  40. Colquhoun D, Jackson R, Walters M, Hicks B, Goldsmith J, Young P et al. Effects of simvastatin on blood lipids, vitamin E, coenzyme Q10 levels and left ventricular function in humans. Eur J Clin Invest 2005; 35: 251–258.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This study was supported by the Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP, Foundation for the Support of Research in the State of São Paulo).

Author information

Authors and Affiliations

  1. Division of Nephrology, Hypertension and Cardiovascular Metabology Center, Kidney and Hypertension Hospital, Federal University of São Paulo, São Paulo, Brazil

    A A Teixeira, A Buffani, A Tavares, A B Ribeiro, M T Zanella, O Kohlmann Jr & M C Batista

Authors
  1. A A Teixeira
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A Buffani
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A Tavares
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A B Ribeiro
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M T Zanella
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. O Kohlmann Jr
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. M C Batista
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A A Teixeira.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Teixeira, A., Buffani, A., Tavares, A. et al. Effects of fluvastatin on insulin resistance and cardiac morphology in hypertensive patients. J Hum Hypertens 25, 492–499 (2011). https://doi.org/10.1038/jhh.2010.87

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/jhh.2010.87

Keywords

This article is cited by

Search

Advanced search

Quick links